Zeitschriftenartikel zum Thema „Abstract Targeted radionuclide therapy (TRT)“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Abstract Targeted radionuclide therapy (TRT)" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Nguyen, Thanh Phuong T., Caroline P. Kerr, Joseph J. Grudzinski, Carolina A. Ferreira, Julia Sheehan-Klenk, Ohyun Kwon, Maria Powers et al. „Abstract 6407: Radionuclide-specific effects of90Y-,177Lu-, or225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhanced immunotherapy response in syngeneic murine tumors“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 6407. http://dx.doi.org/10.1158/1538-7445.am2023-6407.
Der volle Inhalt der QuelleKerr, Caroline P., Joseph J. Grudzinski, Carolina A. Ferreira, David Adam, Julia Sheehan-Klenk, Amber M. Bates, Won Jong Jin et al. „Abstract 2828: Impact of sequencing of immune checkpoint blockade and targeted radionuclide therapy on murine tumor response“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 2828. http://dx.doi.org/10.1158/1538-7445.am2023-2828.
Der volle Inhalt der QuellePal, Debjani, Miguel Toro Gonzáleza, Amber N. Bibleb, Brian Sanders, Anna Plechaty, Owee Kirpekar, Mircea Podar und Sandra M. Davern. „Abstract 480: Nanotherapeutic strategies to improve targeted radionuclide therapy“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 480. http://dx.doi.org/10.1158/1538-7445.am2024-480.
Der volle Inhalt der QuelleAdhikarla, Vikram, Dennis Awuah, Alexander B. Brummer, Enrico Caserta, Amrita Krishnan, Flavia Pichiorri, Megan M. Minnix et al. „Abstract 2732: A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 2732. http://dx.doi.org/10.1158/1538-7445.am2022-2732.
Der volle Inhalt der QuelleKerr, Caroline P., Amber M. Bates, Joseph J. Grudzinski, Carolina A. Ferreira, Julia Sheehan-Klenk, David Adam, Maria Powers et al. „Abstract 1306: Radionuclide-specific effects of 90Y-, 177Lu-, or 225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhancing immunotherapy response in murine tumor models“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 1306. http://dx.doi.org/10.1158/1538-7445.am2022-1306.
Der volle Inhalt der QuelleAdhikarla, Vikram, Dennis Awuah, Enrico Caserta, Megan Minnix, Maxim Kuznetsov, Amrita Krishnan, Jeffrey Y. Wong et al. „Abstract 7374: Mathematical modeling of targeted radionuclide therapy and CAR-T cell immunotherapy for maximizing therapeutic efficacy in multiple myeloma“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 7374. http://dx.doi.org/10.1158/1538-7445.am2024-7374.
Der volle Inhalt der QuelleRuder, Samuel, Michael Sun, Andres Ricaurte Fajardo, Jones Nauseef, Zachary Davidson, Joseph Thomas, Sandra Huicochea Castellanos et al. „Abstract 7582: Descriptive analysis of patients with mCRPC and liver metastases receiving alpha and beta PSMA targeted radionuclide therapy (PSMA-TRT)“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 7582. http://dx.doi.org/10.1158/1538-7445.am2024-7582.
Der volle Inhalt der QuelleSheehan-Klenk, Julia, Caroline P. Kerr, Thanh P. Nguyen, Joseph J. Grudzinski, David Adam, Maria Powers, Raghava N. Sriramaneni et al. „Abstract 6117: Dose, dose rate, and linear energy transfer influence tumor immunologic and DNA damage response following alpha- and beta-emitting radionuclides“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 6117. http://dx.doi.org/10.1158/1538-7445.am2023-6117.
Der volle Inhalt der QuelleVorontsova, M., T. Karmakova, A. Pankratov und A. Kaprin. „Current Trends in Targeted Radionuclide Therapy Development“. Medical Radiology and radiation safety 66, Nr. 6 (17.12.2021): 63–70. http://dx.doi.org/10.12737/1024-6177-2021-66-6-63-70.
Der volle Inhalt der Quellevan der Wal, Bart C. H., und Ekaterina Dadachova. „Targeted Radionuclide Therapy of Cancer and Infections“. International Journal of Molecular Sciences 24, Nr. 10 (22.05.2023): 9081. http://dx.doi.org/10.3390/ijms24109081.
Der volle Inhalt der QuelleMetcalf, Julie, Alexander Nielsen, Suma Prabhu, Nicole Robinson, Sarah Marinacci, Natalie Grinshtein, Brigitte L. Theriault et al. „Abstract LB313: EGFRvIII-targeted alpha therapy shows significant therapeutic efficacy as both a single-agent and in combination with standard of care against preclinical GBM models“. Cancer Research 83, Nr. 8_Supplement (14.04.2023): LB313. http://dx.doi.org/10.1158/1538-7445.am2023-lb313.
Der volle Inhalt der QuelleKerr, Caroline P., Joseph J. Grudzinski, Thanh Phuong Nguyen, Reinier Hernandez, Jamey P. Weichert und Zachary S. Morris. „Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment“. Pharmaceutics 15, Nr. 1 (30.12.2022): 128. http://dx.doi.org/10.3390/pharmaceutics15010128.
Der volle Inhalt der QuelleObata, Honoka, Mikako Ogawa und Michael R. Zalutsky. „DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy“. Pharmaceutics 15, Nr. 7 (11.07.2023): 1926. http://dx.doi.org/10.3390/pharmaceutics15071926.
Der volle Inhalt der QuelleLi, Mengshi, Edwin A. Sagastume, Dongyoul Lee, Daniel McAlister, Anthony J. DeGraffenreid, Keith R. Olewine, Stephen Graves et al. „203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer“. Current Medicinal Chemistry 27, Nr. 41 (08.12.2020): 7003–31. http://dx.doi.org/10.2174/0929867327999200727190423.
Der volle Inhalt der QuelleAdhikarla, Vikram, Dennis Awuah, Alexander B. Brummer, Enrico Caserta, Amrita Krishnan, Flavia Pichiorri, Megan Minnix et al. „A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy“. Cancers 13, Nr. 20 (15.10.2021): 5171. http://dx.doi.org/10.3390/cancers13205171.
Der volle Inhalt der QuelleMalcolm, Javian, Nadia Falzone, Boon Lee und Katherine Vallis. „Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response“. Cancers 11, Nr. 2 (25.02.2019): 268. http://dx.doi.org/10.3390/cancers11020268.
Der volle Inhalt der QuelleRuigrok, Eline A. M., Wytske M. van Weerden, Julie Nonnekens und Marion de Jong. „The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research“. Pharmaceutics 11, Nr. 11 (29.10.2019): 560. http://dx.doi.org/10.3390/pharmaceutics11110560.
Der volle Inhalt der QuelleMüller, Cristina, Martin Béhé, Susanne Geistlich, Nicholas P. van der Meulen und Roger Schibli. „Targeted Radiotherapeutics from 'Bench-to-Bedside'“. CHIMIA International Journal for Chemistry 74, Nr. 12 (23.12.2020): 939–45. http://dx.doi.org/10.2533/chimia.2020.939.
Der volle Inhalt der QuellePatel, Ravi B., Reinier Hernandez, Peter Carlson, Joseph Grudzinski, Amber M. Bates, Justin C. Jagodinsky, Amy Erbe et al. „Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade“. Science Translational Medicine 13, Nr. 602 (14.07.2021): eabb3631. http://dx.doi.org/10.1126/scitranslmed.abb3631.
Der volle Inhalt der QuelleSun, M., C. Thomas, J. Stangl-Kremser, A. Fajardo, J. Palmer, J. Thomas, S. Huicochea Castellanos et al. „1822P PSMA-alpha targeted radionuclide therapy (TRT) with or without prior PSMA-beta TRT“. Annals of Oncology 34 (Oktober 2023): S987. http://dx.doi.org/10.1016/j.annonc.2023.09.2770.
Der volle Inhalt der QuelleSpoormans, Kaat, Melissa Crabbé, Lara Struelens, Marijke De Saint-Hubert und Michel Koole. „A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT)“. Pharmaceutics 14, Nr. 10 (22.09.2022): 2007. http://dx.doi.org/10.3390/pharmaceutics14102007.
Der volle Inhalt der QuelleAprile, Carlo, Onelio Geatti, Letizia Canziani und Lorenzo Lodola. „Editorial for the Special Issue “Molecular Biology in Targeted Radionuclide Therapy Radiopharmaceutical Design”“. Current Issues in Molecular Biology 46, Nr. 3 (13.03.2024): 2398–401. http://dx.doi.org/10.3390/cimb46030152.
Der volle Inhalt der QuelleFuneh, Cyprine Neba, Jessica Bridoux, Thomas Ertveldt, Timo W. M. De Groof, Dora Mugoli Chigoho, Parinaz Asiabi, Peter Covens, Matthias D’Huyvetter und Nick Devoogdt. „Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy“. Pharmaceutics 15, Nr. 5 (30.04.2023): 1378. http://dx.doi.org/10.3390/pharmaceutics15051378.
Der volle Inhalt der QuellePotluri, Hemanth, Carolina Ferreira, Joseph Grudzinski, Christopher Massey, Reinier Hernandez, Jamey Weichert und Douglas McNeel. „594 Combination of antigen-specific vaccination and targeted radionuclide therapy improves anti-tumor efficacy in a murine prostate model“. Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A624. http://dx.doi.org/10.1136/jitc-2021-sitc2021.594.
Der volle Inhalt der QuelleDelpassand, Ebrahim S., Mohammad Jawed Hashmi, Julia Kazakin, Omer Nawaz, Gabriella Garufi, Joanne Schindler und Luke Nordquist. „Abstract CT224: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)“. Cancer Research 84, Nr. 7_Supplement (05.04.2024): CT224. http://dx.doi.org/10.1158/1538-7445.am2024-ct224.
Der volle Inhalt der QuelleRuigrok, Eline A. M., Nicole S. Verkaik, Erik de Blois, Corrina de Ridder, Debra Stuurman, Stefan J. Roobol, Dik C. Van Gent, Marion de Jong, Wytske M. Van Weerden und Julie Nonnekens. „Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment“. International Journal of Molecular Sciences 23, Nr. 14 (21.07.2022): 8037. http://dx.doi.org/10.3390/ijms23148037.
Der volle Inhalt der QuelleWilliams, L. „WE-E-214-03: Biology and Physiology of Targeted Radionuclide Therapy (TRT)“. Medical Physics 38, Nr. 6Part33 (Juni 2011): 3822. http://dx.doi.org/10.1118/1.3613392.
Der volle Inhalt der QuelleSpeer, T. W., P. Bernhardt, B. Bednarz, P. Harari, J. Saker und B. Thomadsen. „Feasibility of the Systemic Cure of Cancer With Targeted Radionuclide Therapy (TRT)“. International Journal of Radiation Oncology*Biology*Physics 84, Nr. 3 (November 2012): S709. http://dx.doi.org/10.1016/j.ijrobp.2012.07.1898.
Der volle Inhalt der QuellePotluri, Hemanth K., Carolina A. Ferreira, Joseph Grudzinski, Christopher Massey, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Ohyun Kwon et al. „Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors“. Journal for ImmunoTherapy of Cancer 10, Nr. 8 (August 2022): e005060. http://dx.doi.org/10.1136/jitc-2022-005060.
Der volle Inhalt der QuelleAkil, Hussein, Mercedes Quintana, Jérémy H. Raymond, Tommy Billoux, Valentin Benboubker, Sophie Besse, Philippe Auzeloux et al. „Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma“. Cancers 13, Nr. 6 (20.03.2021): 1421. http://dx.doi.org/10.3390/cancers13061421.
Der volle Inhalt der QuelleMüller, Cristina, Maria De Prado Leal, Marco D. Dominietto, Christoph A. Umbricht, Sairos Safai, Rosalind L. Perrin, Martina Egloff et al. „Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute“. Pharmaceutics 11, Nr. 9 (02.09.2019): 450. http://dx.doi.org/10.3390/pharmaceutics11090450.
Der volle Inhalt der QuelleMdanda, Sipho, Lindokuhle M. Ngema, Amanda Mdlophane, Mike M. Sathekge und Jan Rijn Zeevaart. „Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review“. Pharmaceutics 15, Nr. 6 (13.06.2023): 1719. http://dx.doi.org/10.3390/pharmaceutics15061719.
Der volle Inhalt der QuelleSun, M., C. Thomas, F. Orlando, M. Sigouros, J. Osborne, J. Nauseef, A. M. Molina et al. „1390P Circulating tumor DNA (ctDNA) and prognosis with PSMA-targeted radionuclide therapy (TRT)“. Annals of Oncology 33 (September 2022): S1179. http://dx.doi.org/10.1016/j.annonc.2022.07.1522.
Der volle Inhalt der Quellede Roode, Kim E., Lieke Joosten und Martin Behe. „Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands“. Pharmaceuticals 17, Nr. 2 (16.02.2024): 256. http://dx.doi.org/10.3390/ph17020256.
Der volle Inhalt der QuelleCortiana, Viviana, Jade Gambill, Harshal Chorya, Diksha Mahendru, Fabiha Amin, Chandler H. Park und Yan Leyfman. „PSMA-Targeted Therapy: Advancements in Detection and Treatment Modalities with Dr. Scott T. Tagawa“. Cancers 16, Nr. 10 (11.05.2024): 1833. http://dx.doi.org/10.3390/cancers16101833.
Der volle Inhalt der QuelleSun, Michael, Charlene Thomas, Benedict Ho, Muhammad Junaid Niaz, Ana M. Molina, Cora N. Sternberg, David M. Nanus, Neil Harrison Bander und Scott T. Tagawa. „Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).“ Journal of Clinical Oncology 39, Nr. 15_suppl (20.05.2021): 5055. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.5055.
Der volle Inhalt der QuelleThomas, Joseph Earl, Jones T. Nauseef, Michael Philip Sun, Amie Patel, Angela Tan, Mahelia Bissassar, Jyothi Manohar et al. „Increased utilization of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (PSMA-TRT) in African American (AA) patients at an academic medical center.“ Journal of Clinical Oncology 41, Nr. 6_suppl (20.02.2023): 36. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.36.
Der volle Inhalt der QuelleSodji, Quaovi H., Matthew H. Forsberg, Dan Cappabianca, Caroline P. Kerr, Lauren Sarko, Amanda Shea, David P. Adam et al. „Comparative Study of the Effect of Radiation Delivered by Lutetium-177 or Actinium-225 on Anti-GD2 Chimeric Antigen Receptor T Cell Viability and Functions“. Cancers 16, Nr. 1 (30.12.2023): 191. http://dx.doi.org/10.3390/cancers16010191.
Der volle Inhalt der QuelleLi, Mengshi, Dijie Liu, Dongyoul Lee, Yinwen Cheng, Nicholas J. Baumhover, Brenna M. Marks, Edwin A. Sagastume et al. „Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma“. Cancers 13, Nr. 15 (22.07.2021): 3676. http://dx.doi.org/10.3390/cancers13153676.
Der volle Inhalt der QuelleEverix, Liesbeth, Shankari Nair, Cathryn H. S. Driver, Ingeborg Goethals, Mike M. Sathekge, Thomas Ebenhan, Charlot Vandevoorde und Julie Bolcaen. „Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma“. Cancers 14, Nr. 7 (03.04.2022): 1821. http://dx.doi.org/10.3390/cancers14071821.
Der volle Inhalt der QuelleMagee, Kara, Ian R. Marsh, Michelle M. Turek, Joseph Grudzinski, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Ilene D. Kurzman et al. „Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting“. PLOS ONE 16, Nr. 8 (12.08.2021): e0255798. http://dx.doi.org/10.1371/journal.pone.0255798.
Der volle Inhalt der QuelleMuralidhar, Anusha, Reinier Hernandez, Zachary S. Morris, Hansel Comas Rojas, Malick Bio Idrissou, Jamey P. Weichert und Douglas G. McNeel. „Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using90Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors“. Journal for ImmunoTherapy of Cancer 12, Nr. 4 (April 2024): e008760. http://dx.doi.org/10.1136/jitc-2023-008760.
Der volle Inhalt der QuelleMétivier, Cassandra, Patricia Le Saëc, Joëlle Gaschet, Catherine Chauvet, Séverine Marionneau-Lambot, Peter O. Hofgaard, Bjarne Bogen et al. „Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma“. Pharmaceutics 15, Nr. 7 (25.06.2023): 1817. http://dx.doi.org/10.3390/pharmaceutics15071817.
Der volle Inhalt der QuelleVlachostergios, Panagiotis J., Muhammad Junaid Niaz, Seyed Ali Mosallaie, Paul J. Christos, Amy Hackett, Joseph R. Osborne, Yuliya Jhanwar et al. „Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).“ Journal of Clinical Oncology 37, Nr. 15_suppl (20.05.2019): 5013. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5013.
Der volle Inhalt der QuelleReiner, Dora, Matthias Blaickner und Frank Rattay. „Discrete beta dose kernel matrices for nuclides applied in targeted radionuclide therapy (TRT) calculated withMCNP5“. Medical Physics 36, Nr. 11 (02.10.2009): 4890–96. http://dx.doi.org/10.1118/1.3231995.
Der volle Inhalt der QuelleSun, Michael, Justin M. Lebenthal, Jones T. Nauseef, Muhammad Junaid Niaz, Sabrina Guervil, Escarleth Fernandez, Amie Patel et al. „Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).“ Journal of Clinical Oncology 39, Nr. 6_suppl (20.02.2021): 158. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.158.
Der volle Inhalt der QuelleFernandes, Célia, Elisa Palma, Francisco Silva, Ana Belchior, Catarina I. G. Pinto, Joana F. Guerreiro, Hugo M. Botelho, Filipa Mendes, Paula Raposinho und António Paulo. „Searching for a Paradigm Shift in Auger-Electron Cancer Therapy with Tumor-Specific Radiopeptides Targeting the Mitochondria and/or the Cell Nucleus“. International Journal of Molecular Sciences 23, Nr. 13 (29.06.2022): 7238. http://dx.doi.org/10.3390/ijms23137238.
Der volle Inhalt der QuelleRao, Yi, Tara Viray, Kurt Gehlsen, Matt Harris, Lachlan McInnes, Olufolake Majekodunmi und Jason Lewis. „Abstract 6038: Copper-67 based targeted radiotherapy primes immunologically cold PDAC for immunotherapy“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 6038. http://dx.doi.org/10.1158/1538-7445.am2024-6038.
Der volle Inhalt der QuelleRuder, Samuel Francis, Michael Philip Sun, Charlene Thomas, Ana M. Molina, Jones T. Nauseef, Joseph Osborne, Cora N. Sternberg, David M. Nanus, Neil Harrison Bander und Scott T. Tagawa. „Comparison of adverse event rate of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with antibody or small molecule ligand targeting vector.“ Journal of Clinical Oncology 42, Nr. 4_suppl (01.02.2024): 161. http://dx.doi.org/10.1200/jco.2024.42.4_suppl.161.
Der volle Inhalt der QuelleSanchez-Garcia, Manuel, Isabelle Gardin, Rachida Lebtahi und Arnaud Dieudonné. „A new approach for dose calculation in targeted radionuclide therapy (TRT) based on collapsed cone superposition: validation with90Y“. Physics in Medicine and Biology 59, Nr. 17 (06.08.2014): 4769–84. http://dx.doi.org/10.1088/0031-9155/59/17/4769.
Der volle Inhalt der Quelle